Is Talanx AG's (ETR:TLX) ROE Of 8.8% Impressive?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Equity (ROE). We'll use ROE to examine Talanx AG (ETR:TLX), by way of a worked example.

Talanx has a ROE of 8.8%, based on the last twelve months. That means that for every €1 worth of shareholders' equity, it generated €0.088 in profit.

Check out our latest analysis for Talanx

Advertisement

How Do You Calculate Return On Equity?

The formula for return on equity is:

Return on Equity = Net Profit ÷ Shareholders' Equity

Or for Talanx:

8.8% = €720m ÷ €16b (Based on the trailing twelve months to March 2019.)

Most know that net profit is the total earnings after all expenses, but the concept of shareholders' equity is a little more complicated. It is the capital paid in by shareholders, plus any retained earnings. The easiest way to calculate shareholders' equity is to subtract the company's total liabilities from the total assets.

What Does Return On Equity Signify?

Return on Equity measures a company's profitability against the profit it has kept for the business (plus any capital injections). The 'return' is the yearly profit. The higher the ROE, the more profit the company is making. So, all else being equal, a high ROE is better than a low one. That means ROE can be used to compare two businesses.

Does Talanx Have A Good Return On Equity?

One simple way to determine if a company has a good return on equity is to compare it to the average for its industry. The limitation of this approach is that some companies are quite different from others, even within the same industry classification. The image below shows that Talanx has an ROE that is roughly in line with the Insurance industry average (8.1%).

XTRA:TLX Past Revenue and Net Income, August 1st 2019
XTRA:TLX Past Revenue and Net Income, August 1st 2019

That's neither particularly good, nor bad. ROE tells us about the quality of the business, but it does not give us much of an idea if the share price is cheap. I will like Talanx better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

How Does Debt Impact ROE?

Companies usually need to invest money to grow their profits. That cash can come from issuing shares, retained earnings, or debt. In the first two cases, the ROE will capture this use of capital to grow. In the latter case, the use of debt will improve the returns, but will not change the equity. In this manner the use of debt will boost ROE, even though the core economics of the business stay the same.

Talanx's Debt And Its 8.8% ROE

Although Talanx does use debt, its debt to equity ratio of 0.32 is still low. The combination of modest debt and a very respectable ROE suggests this is a business worth watching. Careful use of debt to boost returns is often very good for shareholders. However, it could reduce the company's ability to take advantage of future opportunities.

The Key Takeaway

Return on equity is useful for comparing the quality of different businesses. In my book the highest quality companies have high return on equity, despite low debt. If two companies have the same ROE, then I would generally prefer the one with less debt.

Having said that, while ROE is a useful indicator of business quality, you'll have to look at a whole range of factors to determine the right price to buy a stock. The rate at which profits are likely to grow, relative to the expectations of profit growth reflected in the current price, must be considered, too. So you might want to take a peek at this data-rich interactive graph of forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

M
mitchell_lawler
mitchell_lawler

When oil spikes, crude gets the attention. I think the boring refiner in the middle is where it gets interesting, and a record shows why.

0
Andrew Legget

Great earnings season, but are the earnings real?

Great earnings season, but are the earnings real? cover
At first glance, this was the strongest earnings season in years. But when you look at where the growth actually came from, the story splits into two very different pictures.
85

About XTRA:TLX

Talanx

Provides insurance and reinsurance products and services worldwide.

Undervalued established dividend payer.

Advertisement

Weekly Picks

LO
Lou_Basenese
ONCY logo
Lou_Basenese on Oncolytics Biotech ·

The Team Behind a $2 Billion Johnson & Johnson (JNJ) Deal Just Took Over This $105 Million Cancer Biotech

Fair Value:US$3.576.0% undervalued
45 users have followed this narrative
0 users have commented on this narrative
12 users have liked this narrative
AN
andrei9868
Emerging Author
NOW logo
andrei9868 on ServiceNow ·

The Platform Turning Enterprise Chaos into Autonomous Workflows

Fair Value:US$17015.9% undervalued
23 users have followed this narrative
2 users have commented on this narrative
5 users have liked this narrative
JO
John_Eric
Emerging Author
VST logo
John_Eric on Vistra ·

Vistra Fell 38%. Adjusted EBITDA Rose 31%. Here's the $472 Million Reason They Disagree.

Fair Value:US$291.8752.7% undervalued
9 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
HA
HarishPK
Emerging Author
EVER logo
HarishPK on EverQuote ·

EverQuote and an Asymmetric Investment Opportunity

Fair Value:US$36.0931.2% undervalued
5 users have followed this narrative
1 users have commented on this narrative
3 users have liked this narrative

Updated Narratives

DE
Deep_Insights
HIMS logo
Deep_Insights on Hims & Hers Health ·

Hims & Hers Health Multidimensional Revenue Expansion

Fair Value:US$173.0283.6% undervalued
73 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
StoxEurope
UCB logo
StoxEurope on UCB ·

FV 206,24 but with a 310-154 range...to discuss

Fair Value:€227.494.0% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
RockeTeller
HSTR logo
RockeTeller on Heliostar Metals ·

Heliostar Metals, From 50k to 500k oz Producer Monster by 2030?

Fair Value:CA$23.5390.8% undervalued
28 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28022.3% undervalued
374 users have followed this narrative
9 users have commented on this narrative
17 users have liked this narrative
JO
John_Eric
Emerging Author
MELI logo
John_Eric on MercadoLibre ·

MercadoLibre and the Spreadsheet Trick That Decides Everything

Fair Value:US$7.31k73.2% undervalued
128 users have followed this narrative
3 users have commented on this narrative
18 users have liked this narrative
CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.9119.3% overvalued
218 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative

Trending Discussion